GGrantIndex
← Search

RADIATION ONCOLOGY

$78,870U10FY2002CANIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Paper 39055377Paper 37539667Paper 36050448Paper 35859079Paper 34804634Paper 33154022Paper 32923882Paper 32504284Paper 31802506Paper 31213748Paper 30775161Paper 29848457Paper 29649081Paper 29530935Paper 29313954Paper 29164377Paper 29138761Paper 29044496Paper 28939223Paper 28921241Paper 28917648Paper 28786105Paper 28700816Paper 28691116Paper 28691057Paper 28687377Paper 28649983Paper 28646344Paper 28620884Paper 28533226Paper 28493308Paper 28402581Paper 28384065Paper 28375706Paper 28323331Paper 28280603Paper 28262692Paper 28239505Paper 28089762Paper 28006055Paper 27943153Paper 27881709Paper 27590208Paper 27534963Paper 27478689Paper 27468630Paper 27458945Paper 27374464Paper 27365012Paper 27302508Paper 27197192Paper 27098150Paper 27075674Paper 27060850Trial NCT01648348Trial NCT01369849Trial NCT01086605Trial NCT00869401Trial NCT00826540Trial NCT00738881Trial NCT00731731Trial NCT00699491Trial NCT00684983Trial NCT00641706Trial NCT00528645Trial NCT00459862Trial NCT00398112Trial NCT00369655Trial NCT00329719Trial NCT00321724Trial NCT00316849Trial NCT00255762Trial NCT00238394Trial NCT00238303Trial NCT00110084Trial NCT00109967Trial NCT00098540Trial NCT00096434Trial NCT00096070Trial NCT00093756Trial NCT00079274Trial NCT00079235Trial NCT00052949Trial NCT00052689Trial NCT00049127Trial NCT00039494Trial NCT00033267Trial NCT00027612Trial NCT00026234Trial NCT00026182Trial NCT00016328Trial NCT00015990Trial NCT00015821Trial NCT00014170Trial NCT00006226Trial NCT00005970Trial NCT00005036Trial NCT00003869Trial NCT00003140Patent 8507518

Abstract

During the last grant period, the Radiation Oncology Committee continued its active role in all the North Central Oncology Committee its active role in all the North Central Cancer Treatment Group disease- oriented committees, with several members serving in leadership capacities. This involvement took the form of providing ideas for clinical trials, helping to develop studies, and carrying out high quality radiation therapy for patients entered onto Group protocols. The Committee is comprised of community radiation oncologists working in concert with Research Base radiation oncologists from the Mayo Clinic. Phase III trials employing radiation therapy and asking important radiation therapy questions have been conducted during the last grant period in cancers of the lung, breast, GI tract, and central nervous system. A number of pilot studies addressed radiation therapy issues, and symptom-control studies evaluated measures to ameliorate a variety of adverse radiation sequelae. Studies have also been completed during this grant period utilizing the NCCTG clinical database to address important radiation-related questions. Members of the Committee continue to provide high quality radiation therapy for group protocols. This is evidenced by a major deviation rate of less than 10% for the last five years. During the next grant period, the Radiation Oncology Committee will continue all of these activities, thus maintaining its vital role in the Group. The Committee will foster the evaluation of high quality radiation therapy in combined modality studies. One future focus for the Committee will be combined modality approaches using new agents (some of which may prove to be radiation enhancers) identified by the Group's Novel Therapeutics Committee.

View original record on NIH RePORTER →